Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia - Episode 15

Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

August 15, 2024

Elias Jabbour, MD, Evandro D. Bezerra, MD, Lori Muffly, MD, Jae H. Park, MD, Gregory W. Roloff, MD

Experts evaluate the frequency of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T therapy, comparing their incidence to that observed with other immunotherapies such as bispecific antibodies.

EP. 1: Overview of CAR T-cell Therapies in R/R B-cell ALL

EP. 2: CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

EP. 3: Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL

EP. 4: Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment

EP. 5: Overview of Available Treatment Options in R/R B-cell ALL

EP. 6: Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

EP. 7: Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data

EP. 8: Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL

EP. 9: Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy

EP. 10: Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment

EP. 11: Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting

EP. 12: Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL

EP. 13: Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy

EP. 14: Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL

Now Viewing

EP. 15: Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

EP. 16: Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

EP. 17: Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

EP. 18: Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy

EP. 19: Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting

EP. 20: Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

Video content above is prompted by the following:

How frequently do you see severe CRS and ICANs with CAR-T, and how does that compare to other therapies like Bispecific-Antibodies?
Does developing severe CRS or ICANS correlate with long-term outcomes?
Are there risk factors that can predict those who are at higher risk for developing severe CRS and/or ICANs?